Page 2 - Read Online

Topic: Immunotherapy and

Immunotherapy Biomarkers for

Hepatocellular Carcinoma

Immune checkpoint inhibitor agents are now globally available for use in first-
line or second-line treatment of unresectable hepatocellular carcinoma (HCC).
However, objective responses to these agents occur in only a small fraction
of patients, and a reliable tissue, serum, or imaging biomarker for predicting
therapeutic response has yet to be identified. The pathways and mechanisms
Sandi Alexander underlying the development of immunotherapy resistance are also poorly
understood, and clinically, there still exists a need to further define the role
Kwee, MD, PhD of biomarkers for immune checkpoint inhibitors used alone or in combination
with other therapies including liver-directed therapies. For this Special Issue on
Associate Professor, immunotherapy and immunotherapy biomarkers in HCC, we include original
Clinical and articles, perspectives, and reviews of clinical and pre-clinical research that
Translational Sciences support the goal of improving HCC immunotherapy effectiveness and precision.
Program, University of
Hawaii Cancer Center,
and John A. Burns
School of Medicine,
University of Hawaii,
Honolulu, HI, USA.